ABC | Volume 111, Nº6, December 2018

Original Article Einwoegerer & Domingueti Cystatin C and cardiovascular event or mortality Arq Bras Cardiol. 2018; 111(6):796-807 19. Sai E, Shimada K, Miyauchi K, Masaki Y, Kojima T, Miyazaki T, et al. Increased cystatinClevelsasariskfactorofcardiovasculareventsinpatientswithpreserved estimated glomerular filtration rate after elective percutaneous coronary interventionwith drug‑eluting stents. Heart Vessels. 2016;31(5):694-701. 20. AlehagenU, DahlströmU, Lindahl TL. CystatinC andNT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur J Heart Fail. 2009;11(4):354-60. 21. GaoC, Zhong L, Gao Y, Li X, ZhangM,Wei S. CystatinC levels are associated with the prognosis of systolic heart failure patients. Arch Cardiovasc Dis. 2011;104(11):565-71. 22. Ge C, Ren F, Lu S, Ji F, Chen X, Wu X. Clinical prognostic significance of plasma cystatin C levels among patients with acute coronary syndrome. Clin Cardiol. 2009;32(11):644-8. 23. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of Cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease data from the Heart and Soul Study. Circulation. 2007;115(2):173-9. 24. KoeningW. Is elevated cystatin C a predictor of cardiovascular risk in elderly people without chronic kidney disease? Nat Clin Pract Cardiovasc Med. 2007;4(2):76-7. 25. Guyton AC, Hall JE. Tratado de Fisiologia Médica. 12ª. ed. Rio de Janeiro: Elsevier; 2011. p. 870-1. 26. LiuJ,SukhovaGK,SunJS,XuWH,LibbyP,ShiGP.Lysosomalcysteineproteases in atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24(8):1359-66. 27. Eriksson P, Jones KG, Brown LC, Greenhalgh RM, Hamsten A, Powell JT. Genetic approach to the role of cysteine proteases in the expansion of abdominal aortic aneurysms. Br J Surg. 2004;91(1):86-9. 28. Prates AB, Amaral FB, Vacaro MZ, Gross JL, Camargo JL, Silveiro SP. Glomerular filtration evaluation employing serum cystatin Cmeasurement. J Bras Nefrol. 2013;35(1):48-56. 29. Gabriel IC, Nishida SK, Kirsztajn GM. [Serum cystatin C: a practical alternative for renal function evaluation?] J Bras Nefrol. 2011;33(2):261-7. 30. Moura RS. Cistatina C em pacientes com hipertensão arterial essencial: Avaliação da função renal e correlação com fatores de risco cardiovascular [Dissertação]. Brasília: Universidade de Brasília; 2010. 31. Porto JR, Gomes KB, Fernandes AP, Domingueti CP. Avaliação da função renal na doença renal crônica. RBAC. 2017;49(1):26-35. 32. Pucci L, Triscorna S, Lucchesi D, Fotino C, Pellegrini G, Pardini E, et al. Cystatin C and estimatives of renal function: searching a better measure of kidney function in diabetic patients. Clin Chem. 2007;53(3):480-8. 33. Le Bricon T, Thervet E, Froissart M, Benlakehal M, Bousquet B, Legendre C, et al. Plasma cystatin C is superior to 24 h creatinine clearance and plasma creatinine for estimation of glomerular filtration rate 3 months after kidney transplantation. Clin Chem. 2000;46(8 Pt 1):1206-7. 34. Filler G, Bokenkamp A, HofmannW, Le Bricon T, Martínez-Brú C, Grubb A. Cystatin C as a marker of GFR-history, indications, and future research. Clin Biochem. 2005;38(1):1-8. 35. Macissac RJ, Premaratne E, Jerums G. Estimating glomerular filtration rate in diabetes using serum cystatin C. Clin Biochem Rev. 2011;32(2):61-7. 36. Abreu PF, Sesso RC, Ramos LR. Aspectos renais no idoso. J Bras Nefrol. 1998;20(2):158-65. 37. Neri LA, Mendes ME, Neto ED, Sumita NM, Medeiros FS. Determinação de cistatina C como marcador de função renal. J Bras Patol Med Lab. 2010;46(6):443-53. 38. Soares JL, Rosa DD, Leite VR, Pasqualotto AC. Métodos diagnósticos: consulta rápida. 2ª. ed. Porto Alegre: Artmed; 2012. 39. Marotti J, Galhardo AP, Furuyama RJ, PigozzoMN, Campos TN, Laganá DC. Amostragem em pesquisa clínica: tamanho da amostra. Rev Odont Univ Cid São Paulo. 2008;20(2):186-94. 806